On January 31, the Engelberg Center for Health Care Reform hosted the fifth annual Sentinel Initiative public workshop, at the Washington Marriott Wardman Park in Washington, DC. This public workshop brought together the members of various stakeholder communities for a productive discussion on the continuing development of active medical product surveillance, including:
- The State of Mini-Sentinel Activities
- Selected Mini-Sentinel Protocol-Driven Evaluations
- Collaborations Supporting Active Surveillance Research
- Planned Expansion of Prospective Surveillance Programs
- Opportunities to Expand the Public Health Impact of the Sentinel Initiative
- Stakeholder Feedback on Mini-Sentinel as a Tool for Evaluating Drug Safety Issues that Require Regulatory Action
Dr. Janet Woodcock, the Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration, provided the morning keynote address. Both Dr. Woodcock and Dr. Karen Midthun, the Director of the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration participated in a panel seeking input on the ongoing progress as well as the future of the Sentinel Initiative.
Senior Advisor and Scientific Lead for Surveillance Programs - Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administraion
Deputy Director, Division of Epidemiology, Office of Biostatistics and Epidemiology - Center for Biologics Evaluation and Research, US Food and Drug Administration
Harvard Pilgrim Health Care Institute and Harvard Medical School
On the one hand, it's a drop in the ocean, because it won't change what's happening on the ground. On the other hand, it would represent a shift to a more realistic approach toward what's happening in Venezuela. By sanctioning the vice president, the U.S. government is acknowledging that the Venezuelan government has drug dealers at the highest ranks of government.